Adenosine Deaminase Association with Esophageal Cancer from Multi-Level Analysis

Mendelian randomization analysis identified adenosine deaminase (ADA) as a potential risk factor for esophageal cancer (OR = 1.23). This dataset, uploaded by Xiaoling Tian in 2026, contains results from serum validation, transcriptomic analysis, single-cell RNA sequencing, and network pharmacology screening exploring ADA's role and potential TCM interventions.

Use Cases

• Validate genetic risk factors for esophageal cancer based on Mendelian randomization results.
• Analyze ADA co-expression networks based on pathways like 'proteasome' and 'protein folding' mentioned in the description.
• Identify potential drug compounds for ADA targeting based on reverse network pharmacology and molecular docking results.
• Examine cell-type-specific ADA expression based on single-cell RNA sequencing data for plasma cells and plasmacytoid dendritic cells.

Strengths

• Includes multi-level integrative analysis results from Mendelian randomization, serum validation, transcriptomics, and single-cell sequencing.
• Specific statistical result provided: OR = 1.23 (95% CI: 1.00–1.52) for ADA as a risk factor.
• Released under a permissive CC-BY-4.0 license for reuse.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The dataset is very small (73.2 KB), suggesting limited scope or summary-level data.

Provenance

Source

figshare

Collection Method

Multi-level integrative analysis including Mendelian randomization, serum validation, transcriptomics, co-expression networks, single-cell RNA sequencing, network pharmacology, and molecular docking.

Time Range

null

Freshness

Last updated 2026-04 23 04:21:42; freshness should be verified.

Geography

null